» Articles » PMID: 10884427

Direct Selection of a Human Antibody Fragment Directed Against the Tumor T-cell Epitope HLA-A1-MAGE-A1 from a Nonimmunized Phage-Fab Library

Overview
Specialty Science
Date 2000 Jul 8
PMID 10884427
Citations 33
Authors
Affiliations
Soon will be listed here.
Abstract

Antitumor antibodies with the same specificity as cytotoxic T lymphocytes that recognize antigenic peptides encoded by tumor-associated genes and presented by MHC class I molecules would be valuable tools to analyze the antigenicity or target tumor cells in vivo. To obtain a human antibody directed against a peptide encoded by gene melanoma-associated antigen (MAGE)-A1 and presented by HLA-A1 molecules, we selected a large phage Fab antibody repertoire on a recombinant version of the complex HLA-A1-MAGE-A1 produced by in vitro refolding. One of the selected phage antibodies shows binding to HLA-A1 complexed with the MAGE-A1 peptide, but does not show binding to HLA-A1 complexed with a peptide encoded by gene MAGE-A3 and differing from the MAGE-A1 peptide by only three residues. Phages carrying this recombinant antibody bind to HLA-A1(+) cells only after in vitro loading with MAGE-A1 peptide. These results indicate that nonimmunized phage Fab libraries are a source of antibodies with a T cell antigen receptor-like specificity. The human anti-HLA-A1-MAGE-A1 antibody described here may prove very useful for monitoring the cell surface expression of these complexes, and eventually, as a targeting reagent for the specific immunotherapy of HLA-A1 patients bearing a MAGE-A1-positive tumor.

Citing Articles

Unlocking Intracellular Oncology Targets: The Unique Role of Antibody-Based T-Cell Receptor Mimic (TCRm) Therapeutics in T-Cell Engagers (TCEs) and Antibody-Drug Conjugates (ADCs).

Molldrem J, Zha D Cancers (Basel). 2024; 16(22).

PMID: 39594730 PMC: 11592057. DOI: 10.3390/cancers16223776.


Preclinical evaluation of a novel CAR-T therapy utilizing a scFv antibody highly specific to MAGE-A4/HLA-A∗02:01 complex.

Wang L, Matsumoto M, Akahori Y, Seo N, Shirakura K, Kato T Mol Ther. 2024; 32(3):734-748.

PMID: 38243600 PMC: 10928314. DOI: 10.1016/j.ymthe.2024.01.018.


Targeting Intracellular Antigens with pMHC-Binding Antibodies: A Phage Display Approach.

Yang Z, Wu Z, Santich B, Liu J, Liu C, Cheung N Methods Mol Biol. 2023; 2702:327-345.

PMID: 37679628 DOI: 10.1007/978-1-0716-3381-6_17.


Computationally profiling peptide:MHC recognition by T-cell receptors and T-cell receptor-mimetic antibodies.

Raybould M, Nissley D, Kumar S, Deane C Front Immunol. 2023; 13:1080596.

PMID: 36700202 PMC: 9868621. DOI: 10.3389/fimmu.2022.1080596.


T-Cell Receptor Mimic Antibodies for Cancer Immunotherapy.

Duan Z, Ho M Mol Cancer Ther. 2021; 20(9):1533-1541.

PMID: 34172530 PMC: 8419142. DOI: 10.1158/1535-7163.MCT-21-0115.


References
1.
Reisfeld R, Becker J, Gillies S . Immunocytokines: a new approach to immunotherapy of melanoma. Melanoma Res. 1997; 7 Suppl 2:S99-106. View

2.
Andersen P, Stryhn A, Hansen B, Fugger L, Engberg J, Buus S . A recombinant antibody with the antigen-specific, major histocompatibility complex-restricted specificity of T cells. Proc Natl Acad Sci U S A. 1996; 93(5):1820-4. PMC: 39865. DOI: 10.1073/pnas.93.5.1820. View

3.
OCallaghan C, Tormo J, Willcox B, Blundell C, Jakobsen B, Stuart D . Production, crystallization, and preliminary X-ray analysis of the human MHC class Ib molecule HLA-E. Protein Sci. 1998; 7(5):1264-6. PMC: 2143998. DOI: 10.1002/pro.5560070525. View

4.
Hicklin D, Wang Z, Arienti F, Rivoltini L, Parmiani G, Ferrone S . beta2-Microglobulin mutations, HLA class I antigen loss, and tumor progression in melanoma. J Clin Invest. 1998; 101(12):2720-9. PMC: 508863. DOI: 10.1172/JCI498. View

5.
Henderikx P, Kandilogiannaki M, Petrarca C, von Mensdorff-Pouilly S, HILGERS J, Krambovitis E . Human single-chain Fv antibodies to MUC1 core peptide selected from phage display libraries recognize unique epitopes and predominantly bind adenocarcinoma. Cancer Res. 1998; 58(19):4324-32. View